Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Advances in gene therapy have created a dynamic pipeline. A recent Datamonitor Healthcare report examines various trends in that pipeline, including vector types used, in vivo versus ex vivo approaches, and therapy areas being targeted.
Latest From Market Intelligence
As of mid-year 2018, there were more than 950 regenerative medicine therapies in clinical trials, of which more than 90 are in Phase III.
Established in 1999, Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation.
Experiments are underway to solve pharma’s well-documented R&D productivity crisis. The industry is no longer focused only on buying new drugs via M&A, or on outsourcing discovery. Companies are also building new channels through which to access innovation, setting up different kinds of partnerships, and using new kinds of data. The shift involves re-thinking pharma’s place in healthcare.
The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.